p53 mutations in non-small cell lung carcinomas in Hong Kong

被引:22
作者
Lung, ML
Wong, MP
Skaanild, MT
Fok, CL
Lam, WK
Yew, WW
机构
[1] UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG
[2] UNIV HONG KONG,QUEEN MARY HOSP,DEPT PATHOL,HONG KONG,HONG KONG
[3] GRANTHAM HOSP,TB & CHEST UNIT,HONG KONG,HONG KONG
关键词
Hong Kong; lung carcinoma; p53;
D O I
10.1378/chest.109.3.718
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Lung resections from 50 Chinese patients in Hong Kong diagnosed as having non-small cell lung carcinoma were examined for the presence of mutations in the p53 gene by polymerase chain reaction single-stranded conformation polymorphism methods and for aberrant protein expression by immunostaining techniques. Eight-point mutations in the evolutionarily conserved exon 5 through 8 regions were detected. Abnormal expression of p53 detectable by immunostaining techniques was seen in 23 specimens tested. There was no statistically significant correlation between the detection of p53 aberrations and age, sex, smoking history, histologic type, and tumor stage. Aberrant p53 protein levels detectable by immunostaining were significantly associated with the clinical and nodal staging of the tumors.
引用
收藏
页码:718 / 726
页数:9
相关论文
共 50 条
  • [41] Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer
    Cheng, YL
    Lee, SC
    Harn, HJ
    Chen, CJ
    Chang, YC
    Chen, JC
    Yu, CP
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 23 (02) : 221 - 228
  • [42] The XRCC1 codon 399 Gln allele is associated with adenine to guanine p53 mutations in non-small cell lung cancer
    Casse, C
    Hu, YC
    Ahrendt, SA
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2003, 528 (1-2) : 19 - 27
  • [43] TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
    Lee, Eung Bae
    Jin, Guang
    Lee, Shin Yup
    Park, Ji Young
    Kim, Min Jung
    Choi, Jin Eun
    Jeon, Hyo Sung
    Cha, Seung Ick
    Cho, Sukki
    Kim, Chang Ho
    Park, Tae-In
    Jung, Tae Hoon
    Son, Ji-Woong
    Park, Jae Yong
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (05) : 698 - 705
  • [44] Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
    Tung, Min-Che
    Lin, Po-Lin
    Wang, Yao-Chen
    He, Tsung-Ying
    Lee, Ming-Ching
    Yeh, Sauh-Der
    Chen, Chih-Yi
    Lee, Huei
    [J]. ONCOTARGET, 2015, 6 (39) : 41692 - 41705
  • [45] Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer
    Tanaka, F
    Otake, Y
    Yanagihara, K
    Yamada, T
    Miyahara, R
    Kawano, Y
    Li, M
    Inui, K
    Wada, H
    [J]. BRITISH JOURNAL OF CANCER, 2001, 84 (02) : 263 - 269
  • [46] Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy
    Hanaoka, N
    Tanaka, F
    Wada, H
    [J]. THORACIC AND CARDIOVASCULAR SURGEON, 2002, 50 (06) : 355 - 359
  • [47] In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers
    Masahito Ebina
    Alfredo Martínez
    Michael J Birrer
    R Ilona Linnoila
    [J]. Oncogene, 2001, 20 : 2579 - 2586
  • [48] Induction of apoptosis in a non-small cell human lung cancer cell line by isothiocyanates is associated with P53 and P21
    Kuang, YF
    Chen, YH
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2004, 42 (10) : 1711 - 1718
  • [49] DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53
    Muli Wudu
    Hongjiu Ren
    Linping Hui
    Jun Jiang
    Siyang Zhang
    Yitong Xu
    Qiongzi Wang
    Hongbo Su
    Xizi Jiang
    Runa Dao
    Xueshan Qiu
    [J]. Journal of Experimental & Clinical Cancer Research, 38
  • [50] Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations
    Boldrini, L
    Gisfredi, S
    Ursino, S
    Lucchi, M
    Mussi, A
    Basolo, F
    Pingitore, R
    Fontanini, G
    [J]. LUNG CANCER, 2005, 50 (03) : 309 - 317